Communicating Uncertainties About the Benefits and Risks of New Cancer Drugs: Two Randomized Clinical Trials
Menée aux Etats-Unis à partir de données portant sur un échantillon de 6 272 adultes recrutés en ligne pour deux essais cliniques randomisés, cette étude examine l'effet d'une communication explicite concernant les incertitudes liées aux bénéfices et aux risques des nouveaux médicaments anticancéreux sur la décision des patients de prendre ces traitements
Importance : Cancer drugs are frequently approved based on uncertain benefits and risks that are not communicated to patients.
Objective : To evaluate the effect of communicating uncertainties about the benefits and risks of new cancer drugs on changes in individuals’ hypothetical decisions to take the drug.
Design, Setting, and Participants : Two randomized clinical trials recruited online a demographically diverse sample of US adults (census matched for age, sex, education, income, and race and ethnicity) from May 9 to July 26, 2025.
Intervention : Plain-language statements describing uncertainties about drug benefits and risks. Trial 1 randomized participants to 1 of 5 uncertainties: (1) single-arm trial design, (2) unrepresentative population in terms of race and ethnicity, (3) short study duration, (4) surrogate end point, or (5) no noticeable improvement. Trial 2 randomized participants to 1, 2, 3, or 4 uncertainties or to a control group.
Main Outcomes and Measures : The primary outcome in trial 1 was changes in hypothetical decisions to take a new cancer drug (within-group difference), while in trial 2 the primary outcome was the change in between-group differences in hypothetical decisions (control vs intervention groups). Secondary outcomes included perceived treatment effectiveness, worry associated with taking the drug, and trust in the information and the US Food and Drug Administration.
Results : A total of 6272 adults were included in the primary analysis (3102 [49.5%] women). In trial 1, learning about uncertainties reduced hypothetical decisions to take the drug by a mean of 10.1 percentage points (pp; 95% CI, −11.7 to −8.5 pp; P < .001). The reduction in hypothetical decisions to take the drug was observed for all uncertainties, including among those in the group that learned that it was unknown whether patients would notice an improvement with the drug (−14.1 pp; 95% CI, −17.9 to −10.4 pp; P < .001) and those who learned that the drug was not studied in patients of similar race or ethnicity (−12.8 pp; 95% CI, −16.4 to −9.2; P < .001). In trial 2, hypothetical decisions to take the drug decreased with each additional uncertainty, demonstrating a dose-dependent effect. Learning about uncertainties reduced perceived effectiveness and trust but did not affect worry.
Conclusions and Relevance : In 2 randomized clinical trials including a demographically diverse sample of US adults, learning about common uncertainties with a new cancer drug’s benefits and risks reduced hypothetical decisions to take the drug.
Trial Registration : ClinicalTrials.gov Identifiers: NCT06997185 and NCT07110597
JAMA Internal Medicine , résumé, 2026